Abstract Body

Background: With widespread use of combined antiretroviral treatment (cART), overt HIV-1 associated dementia (HAD) is rarely seen. However, milder forms of HIV-associated neurocognitive disorders have frequently been reported also in patients on cART. Hyperphosphorylated tau in CSF (p-tau) is an established biomarker in diagnosis of Alzheimer disease. It increases with age also in healthy subjects and is not influenced by neuroinflammation. In this study we decided to assess whether p-tau can be used as a marker of neurological aging in HIV patients. Methodology: In a cross-sectional retrospective study, CSF concentrations of p-tau (phosphorylated at threonine 181) were measured with an enzyme-linked immunoassay in HIV-1 infected neuroasymptomatic patients without treatment (n=172), in HIV-infected patients on cART and plasma HIV-RNA <50 copies/ml (n=68), in HAD (n=33) and in HIV-negative controls (n=291). For statistical measures, correlations and linear regression were used. Results: The cART group and HIV-negative controls showed significant positive correlations of p-tau and age (p<0.01 and p<0.001 respectively), whereas no significant correlations were found in the NA and HAD groups. When looking at the HIV-positive population as a whole, a significant difference was seen in slope compared to controls (p<0.001). Conclusions: HIV-negative controls and HIV-infected on cART show significant increases of p-tau with age. No such connection could be found in untreated neuroasymptomatics and HAD. Patients with HAD do not have higher p-tau levels than asymptomatic subjects. Several younger untreated HIVinfected subjects, both asymptomatic and with HAD, had high p-tau while this is not the case in older individuals. The mechanism behind this skewness remains to be explained.